| 监测核苷(酸)类抗HBV药物治疗CHB的停药指标 |
| |
| 引用本文： | 刘璐洁,刘妍,刘新光,徐东平. 监测核苷(酸)类抗HBV药物治疗CHB的停药指标[J]. 传染病信息, 2018, 0(3): 203-208. DOI: 10.3969/j.issn.1007-8134.2018.03.003 |
| |
| 作者姓名： | 刘璐洁 刘妍 刘新光 徐东平 |
| |
| 作者单位： | 广东医科大学广东省医学分子诊断重点实验室生物化学与分子生物学研究所;解放军第三○二医院临床研究管理中心 |
| |
| 基金项目： | 北京市科技计划创新课题(首都临床特色应用研究)(Z151100004015011)，国家自然科学基金面上项目(81371852) |
| |
| 摘 要： | 抗HBV感染的治疗难点之一是安全停药或治疗终点的确定,目前主要依靠血清HBV DNA、HBeAg/抗-HBe、HBsAg/抗-HBs和抗-HBc评估慢性乙型肝炎治疗效果,并以持久的HBsAg清除作为停药标准。但血清HBsAg阴转率很低且难以实现"临床治愈(或功能性治愈)",因此,近年来提出了许多新的指导慢性乙型肝炎患者停药的指标,如肝组织HBV ccc DNA、血清HBcrAg和血清HBV RNA。本文就以上指标的研究进展进行综述。
|
| 关 键 词： | 慢性乙型肝炎 核苷(酸)类似物 抗病毒治疗 安全停药 指标 chronic hepatitis B nucleos(t)ide analogues antiviral treatment safe discontinuation indicators |
Indicators for safe withdrawal of nucleos(t)ide analogues antivirals for chronic hepatitis B |
| |
| LIU Lu-jie,LIU Yan,LIU Xin-guang,XU Dong-ping. Indicators for safe withdrawal of nucleos(t)ide analogues antivirals for chronic hepatitis B[J]. Infectious Disease Information, 2018, 0(3): 203-208. DOI: 10.3969/j.issn.1007-8134.2018.03.003 |
| |
| Authors: | LIU Lu-jie LIU Yan LIU Xin-guang XU Dong-ping |
| |
| Abstract: | One of the difficulties in chronic hepatitis B (CHB) treatment is to safely withdraw drugs or determine the endpoint of antiviral therapy. At present, serum HBV DNA, HBeAg/anti-HBe, HBsAg/anti-HBs and anti-HBc are major indicators for evaluating the treatment effect of CHB, and persistent HBsAg loss is considered as the standard of drug withdrawal. However, the proportion of serum HBsAg loss is very low and it's difficult to achieve clinical cure or functional cure. The indicators with potential value for evaluation for drug withdrawal in CHB patients, including intrahepatic HBV cccDNA, serum HBcrAg, and serum HBV RNA are developed in recent years. This paper aims to overview the progress of these indicators. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
